A Comprehensive Bioinformatic Analysis Identifies a Tumor Suppressor Landscape of the MEG3 lncRNA in Breast Cancer
Ahmadi A., Rezaei A., Khalaj-Kondori M., Khajehdehi M.
Laboratory Study, published in Indian J Surg Oncol (2024) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Indian J Surg Oncol (2024)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 39555361
- PMCID
- PMC11564602
- DOI
- 10.1007/s13193-024-01992-0
- Citations
- 2
Abstract (original English)
Breast cancer (BC) is the leading cause of cancer mortality in women and a major risk to world health. Therefore, effective strategies are required for prompt diagnosis and treatment. Nowadays, non-coding RNAs (ncRNAs), particularly long ncRNAs (lncRNAs), have assumed a significant role in the prognosis and diagnosis of diseases, including cancer. In the present study, surveying the bioinformatic tools, including the lncRNADisease v2.0, OncoDB, InteractiVenn, GEPIA, RAID, COXPRESdb, DAVID v6.8, GEO2R, and LncSEA, we proposed the Maternally Expressed Gene (MEG3) as a potential biomarker in BC. This lncRNA significantly downregulates in BC and is associated with tumor size, metastasis, and pathological stage. MEG3 expression is downregulated in several types of primary human cancers and tumor cell lines, which raises the possibility that it could act as a tumor suppressor. The results suggest that MEG3 may play a crucial role in fundamental pathways, including apoptosis, and interact with essential genes and proteins such as P53. It may also be associated with the prognosis, proliferation, migration, invasion, and metastasis of BC.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.